Clostridioides difficile often lives harmlessly in the healthy gut, yet in hospitals it's the single biggest cause of infectious diarrhoea and can progress to life threatening colitis. This guide brings together the UK procedural rules and clinical recommendations clinicians need under the National Institute for Health and Care Excellence and the government frameworks, including the UK Health Security Agency surveillance requirements. It sets out the immediate priorities every clinician must act on: decide whether this is a first episode or a recurrence, and review recent or current antibiotic use because stopping unnecessary antibiotics is both a principal therapy and a central prevention measure. New national guidance is planned for 2027, so trusts and community services should confirm local pathways and formularies are current.

Clinical management requires two simultaneous priorities: decide whether this is a first episode or a recurrence, and immediately review antibiotic exposure because stopping unnecessary antibiotics is both treatment and prevention.

1. Assessment and initial classification

Begin by classifying the episode. Record whether it's a first infection or a relapse, and note individual risk modifiers such as age, frailty and comorbidities that influence the risk of complications or further recurrence. The government guidance makes clear that Clostridioides difficile commonly colonises some healthy adults and many infants without symptoms, but disease typically follows disruption of normal gut flora, most often after antibiotic exposure and particularly in older or immunocompromised people.

Practical example: an 82 year old patient discharged after a course of broad spectrum antibiotics presents with watery diarrhoea. Treat this as a suspected CDI, record that it's a first documented episode unless prior positive tests exist, and list frailty and recent antibiotic use as risk factors that raise the threshold for escalation.

2. Immediate medicines review and basic clinical care

Stop any non essential antibiotic immediately. If an antibiotic must be continued, consider switching to an agent associated with lower risk of precipitating CDI. The NICE recommendations present the medicines review as foundational; it sits at the start of both individual patient management and organisational prevention.

Also review other medicines that can increase risk in the dehydrated patient, including proton pump inhibitors, laxatives, non steroidal anti inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin 2 receptor antagonists and diuretics. Manage fluid losses and supportive care as for acute gastroenteritis, and avoid antimotility agents such as loperamide.

Practical example: a patient in a care home on a PPI and an ACE inhibitor develops diarrhoea after antibiotics. Stop the antibiotic if possible, reassess the indication for the PPI, and prioritise rehydration rather than antimotility treatment while arranging urgent microbiology advice.

3. Diagnosis, reporting and surveillance

Follow the government and UK Health Security Agency guidance on diagnosis and mandatory reporting. The UK Health Security Agency has operated enhanced mandatory surveillance of C. Difficile infection in NHS acute trusts since April 2007, with patient level data submitted monthly. Independent sector organisations that provide regulated care also undertake surveillance.

Local infection prevention teams and microbiology services are the usual points of contact to arrange tests, interpret results and fulfil surveillance reporting requirements. The government collection on C. Difficile guidance, data and analysis sets out the infection characteristics and links to the diagnostic and reporting pathways clinicians must use.

Practical example: on receiving a positive laboratory result the ward infection‑prevention lead should notify the microbiology service, ensure the patient is entered into the local HCAI surveillance flow, and prompt submission of the monthly patient level dataset to the UK Health Security Agency.

4. Antibiotic treatment, recurrence, escalation and infection control

NICE recommends offering an oral antibiotic to treat suspected or confirmed C. Difficile infection for adults and for children and young people under 18 years. Community prescribers should consider obtaining prompt specialist advice from a microbiologist or infectious diseases specialist before starting treatment, and for children treatment should be started by or after advice from a microbiologist, paediatric infectious diseases specialist or paediatric gastroenterologist.

For patients who can't take oral medicines, seek specialist advice about alternative enteral routes such as nasogastric tube or rectal catheter. The NICE guideline text makes clear that the choice of specific agent, dosing and duration is addressed in the full recommendations; prescribers should consult the NICE chapter on choice of antibiotic for drug selection details rather than rely on operational guidance documents.

Practical example: a ward patient who's vomiting and can't tolerate oral therapy should trigger immediate contact with gastroenterology or infectious diseases and pharmacy to plan nasogastric administration, rather than delay or attempt parenteral substitution without specialist input.

Mastheads

NICE advises against offering bezlotoxumab to prevent recurrence because it was judged not to be cost effective. For adults with recurrent infection who have had two or more previous episodes, consider faecal microbiota transplant, referring to the NICE interventional procedures guidance on that technique. Both the government interim guidance and NICE therefore reserve advanced interventions for patients with multiple recurrences or refractory disease, and they place emphasis on specialist involvement before these therapies are used.

Practical example: a patient with three documented episodes over nine months should be discussed with an infectious diseases team about referral for faecal microbiota transplant, after local eligibility and procedural pathways are confirmed.

The government interim guidance superseded the 2008 Health Protection Agency guidance to remove outdated material and to link to newer prevention and management advice. It clarifies which environmental hygiene methods are recognised as effective for preventing spread in health care settings, and aligns definitions used to identify a period of increased incidence.

In practice, infection prevention teams should implement standard C. Difficile control measures in line with local policy and national best practice, notify microbiology and public health colleagues when clusters emerge, and follow local cleaning protocols that target the resilient spores of C. Difficile. The interim guidance reorganised technical appendices into standalone downloadable documents to make specific operational information easier to use.

Practical example: when two or three hospital cases occur in a short period, local thresholds for declaring an incident should be checked, enhanced cleaning protocols enacted and microbiology and public health informed so that heightened surveillance and cluster investigation proceed without delay.

Early specialist contact is a standard step. In community settings clinicians are advised to seek microbiology or infectious diseases specialist input promptly before initiating therapy where possible. In hospital settings involve gastroenterology, microbiology and infection prevention teams early for patients with severe disease, those unable to take oral medication, or patients who are deteriorating. For children, specialist paediatric involvement is required before starting treatment.

Practical example: a child with suspected CDI shouldn't be started on empiric therapy in primary care without prior discussion with a paediatric infectious diseases service or paediatric gastroenterology, and referral pathways must be clear in the local network.

The government portal uses the revised genus name Clostridioides difficile to reflect microbial taxonomy changes, and confirms that the interim guidance supersedes the 2008 HPA document. It records that a review of CDI management and prevention is in progress and that new guidance is planned for publication in 2027. NHS Improvement material and the HCAI data capture system provide operational resources for trusts to meet surveillance and reporting obligations.

Where local policy exists, follow that policy for immediate operational steps but ensure reporting continues into the national surveillance systems. Local infection prevention teams should check which 2008 guidance chapters have been withdrawn or superseded locally and ensure their operational documents reflect the interim guidance where appropriate.

Use a clear six step sequence in frontline practice, recording decisions at each stage so that clinical care and organisational reporting remain aligned.

First, classify the episode as first or recurrent and record risk factors. Second, perform the immediate medication review and stop non essential antibiotics and other drugs that raise risk, while ensuring fluid and symptomatic support and avoiding antimotility agents. Third, obtain microbiological confirmation and liaise with microbiology for diagnosis and reporting; submit the necessary surveillance data to the national systems. Fourth, begin an oral antibiotic according to NICE recommendations, seeking specialist advice in the community and ensuring paediatric cases are started only after specialist consultation. Fifth, for patients unable to take oral therapy or for severe or refractory cases, escalate to gastroenterology, infectious diseases or pharmacy for alternative enteral delivery and for consideration of advanced therapies. Sixth, implement infection control measures and environmental cleaning, and trigger cluster investigation and heightened surveillance if incidence exceeds local thresholds.

Practical worked scenario: an older inpatient develops diarrhoea on day five of a hospital admission while on an unrelated antibiotic. Follow the sequence: classify as suspected first episode, stop the antibiotic if it's not essential, begin fluid replacement and symptomatic care, contact microbiology for testing and early treatment advice and enter the case in local surveillance so monthly submission to the UK Health Security Agency can follow.

Bear in mind the difference in focus between the two main documents: NICE covers treatment specifics including choice of antibiotic and dosing, while the government interim guidance sets out operational control and surveillance instructions and doesn't replace NICE on treatment selection. The government document states the interim guidance is under review and that new guidance will be published in 2027. Local trusts and community services should therefore confirm current local formularies and pathways for antibiotic selection, dosing and specialist referral, and confirm which older 2008 chapters have been withdrawn locally.

For patient care, act immediately: classify the episode, stop non essential antibiotics, manage fluids and symptoms, avoid antimotility drugs, and consult microbiology for diagnosis, reporting and treatment decisions. For organisational compliance, continue monthly patient level reporting to the UK Health Security Agency as required, follow local HCAI surveillance processes and prepare to adopt the updated national guidance when it appears in 2027.

First, classify each case as first or recurrent and record age, frailty and comorbidities.

Second, stop non essential antibiotics and review proton pump inhibitors and other medicines that raise risk, and prioritise rehydration over antimotility drugs.

Third, obtain microbiological confirmation, notify microbiology and infection prevention, and submit patient level data monthly to the UK Health Security Agency.

Fourth, start an oral antibiotic in line with NICE and seek specialist advice promptly in the community and mandatorily for paediatric cases.

Fifth, reserve advanced interventions such as faecal microbiota transplant for patients with multiple recurrences and involve specialists early.

Related Articles

The government interim guidance records that a review of CDI management is under way and that new national guidance will be published in 2027, so trusts and community services should ensure local pathways and formularies are current and that monthly patient level reporting to the UK Health Security Agency continues without interruption.

This article was created with AI assistance.